The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2022

Filed:

Apr. 09, 2019
Applicant:

Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.l.a. China, Beijing, CN;

Inventors:

Wu Zhong, Beijing, CN;

Song Li, Beijing, CN;

Yanqun Zeng, Beijing, CN;

Junhai Xiao, Beijing, CN;

Xinbo Zhou, Beijing, CN;

Zhibing Zheng, Beijing, CN;

Xingzhou Li, Beijing, CN;

Xiaokui Wang, Beijing, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); A61K 31/506 (2006.01); C07D 409/14 (2006.01); A61K 31/404 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
C07D 401/04 (2013.01); A61K 31/404 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 401/14 (2013.01); C07D 409/14 (2013.01);
Abstract

The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.


Find Patent Forward Citations

Loading…